id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-1096-0007,FDA,FDA-2021-D-1096,Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment; Guidance for Industry; Availability,Notice,Notice of Availability,2023-06-30T04:00:00Z,2023,6,2023-06-30T04:00:00Z,,2023-06-30T14:29:33Z,2023-13884,0,0,0900006485c21c2c
FDA-2021-D-1096-0008,FDA,FDA-2021-D-1096,Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment; Guidance for Industry,Other,Guidance,2023-06-30T04:00:00Z,2023,6,2023-06-30T04:00:00Z,,2024-11-12T05:50:22Z,,1,0,0900006485c22fa3